Triple

T22889006
Position Surface form Disambiguated ID Type / Status
Subject CYP2C19 E567681 entity
Predicate metabolizes P37221 FINISHED
Object citalopram NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: citalopram | Statement: [CYP2C19, metabolizes, citalopram]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: citalopram
Context triple: [CYP2C19, metabolizes, citalopram]
  • A. Zoloft
    Zoloft is a widely prescribed antidepressant medication (sertraline) in the selective serotonin reuptake inhibitor (SSRI) class, commonly used to treat depression, anxiety disorders, and related conditions.
  • B. Prozac
    Prozac is a widely prescribed antidepressant medication (fluoxetine) used to treat major depressive disorder, anxiety disorders, and certain other mental health conditions.
  • C. Cymbalta
    Cymbalta is a prescription antidepressant medication (duloxetine) commonly used to treat major depressive disorder, generalized anxiety disorder, and certain types of chronic pain.
  • D. amitriptyline
    Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder, neuropathic pain, and migraine prophylaxis.
  • E. SSRI
    An SSRI (selective serotonin reuptake inhibitor) is a class of antidepressant medications that increase serotonin levels in the brain to treat conditions like depression and anxiety disorders.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: citalopram
Target entity description: Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant commonly prescribed to treat major depressive disorder and related mood conditions.
  • A. Zoloft
    Zoloft is a widely prescribed antidepressant medication (sertraline) in the selective serotonin reuptake inhibitor (SSRI) class, commonly used to treat depression, anxiety disorders, and related conditions.
  • B. Prozac
    Prozac is a widely prescribed antidepressant medication (fluoxetine) used to treat major depressive disorder, anxiety disorders, and certain other mental health conditions.
  • C. Cymbalta
    Cymbalta is a prescription antidepressant medication (duloxetine) commonly used to treat major depressive disorder, generalized anxiety disorder, and certain types of chronic pain.
  • D. amitriptyline
    Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder, neuropathic pain, and migraine prophylaxis.
  • E. SSRI
    An SSRI (selective serotonin reuptake inhibitor) is a class of antidepressant medications that increase serotonin levels in the brain to treat conditions like depression and anxiety disorders.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2458a92ec81908fc1cd5f6407d2ab completed April 17, 2026, 2:36 p.m.
NER Named-entity recognition batch_69f17fc37a448190996e106aacc900f4 completed April 29, 2026, 3:49 a.m.
Created at: April 17, 2026, 3:40 p.m.